Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec
Ataxion, Inc, a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases, has secured Series A financing commitments totaling...
View ArticleSpinoffs from Spyland: How America’s eavesdropping agency...
Chris Lynch, an investor with Atlas Venture, knows this firsthand. Two years ago, he spent weeks trying to sign a deal with nervous NSA programmers who not only were sworn to secrecy but were barred...
View ArticleExclusive: Changes in the Atlas Venture partnership
There are some big changes afoot at Atlas Venture, which has transformed itself into one of the most influential VC firms in Boston .
View ArticleJon Karlen joining Atlas Venture as Fred Destin leaves
Atlas Venture is expected to add Jon Karlen as a new tech-focused partner, according to Fortune's Dan Primack.
View ArticleSpero Formed to Develop First-in-Class Therapeutics for Drug-Resistant...
Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche.
View ArticleFreelancer Marketplace Ooomf Becomes Crew, Grabs $2.1 Million
Ooomf , the one-time app discovery startup which last year r elaunched as a freelancer marketplace to connect mobile and web developers with projects that fit their skill set, is now changing its name...
View ArticleThe Currency Cloud, An API-Based Money Mover, Raises Another $10M
With the news that Facebook has been talking to financial services startups in the UK about launching e-money services, one of the companies that powers payments for those startups has raised a round...
View ArticleAngelList Unveils Maiden Lane, A $25 Million Fund For AngelList Deals
AngelList is working on a new project called Maiden Lane . Behind this name is a new experiment in startup investment.
View ArticleCambridge security software startup Threat Stack raises $2.7M
Cambridge startup Threat Stack, a TechStars alum offering security software aimed at the cloud, has raised $2.7 million in funding, according to a U.S. Securities and Exchange Commission filing.
View ArticlePhoto tech company Vhoto raises $2.4 mln in seed
Vhoto , which develops photo capturing technology, announced it has raised a $2.4 million dollar seed round from Atlas Venture , Polaris Partners and Hugh Crean , company co-founder and chairman and...
View ArticleLysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
Lysosomal Therapeutics Inc. , a company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has...
View ArticleAtlas Venture leads seed round for Lysosomal Therapeutics
Lysosomal Therapeutics has secured $4.8 million in seed funding. Atlas Venture led the round with participation from Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture...
View ArticleVenture capitalist Fred Destin joins Accel London
Last month we reported that Destin was leaving Boston-based Atlas Venture after more than a decade, largely so that his family could move back to Europe.
View ArticleAtlas Venture names new partner for life science startups
A managing director for the past four years at Atlas Venture who has helped start three early-stage biotech firms is now a partner at the firm.
View ArticleAtlas Venture names new partner for life science startups
A managing director for the past four years at Atlas Venture who has helped start three early-stage biotech firms is now a partner at the firm.
View ArticleUnited States : Atlas Venture appoints Dave Grayzel as new partner
The firm has targeted on acquiring drug assets and partnering with pharmaceutical companies to commercialize them.
View ArticleRodin Secures $12.9M Series A Financing to Develop Novel Treatments for CNS...
Current investors Atlas Venture and Johnson & Johnson Development Corporation led the financing round.
View ArticleTwo more local biotech IPOs on tap for next week signal a market rebound
Zafgen CEO Thomas Hughes. The company's biggest backers are Atlas Venture in Cambridge and Third Rock Ventures in Boston.
View ArticleZafgen shares up following $96M IPO on strength of obesity drug
Zafgen CEO Thomas Hughes. The company's biggest backers are Atlas Venture in Cambridge and Third Rock Ventures in Boston.
View ArticleNumerate Closes New Round of Financing
Concurrent with the financing, Bruce Booth, Ph.D, Partner at Atlas Venture , and Steve Hall, Ph.D., Venture Partner at Lilly Ventures , have joined the Numerate Board of Directors.
View Article
